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A 20-year-old white man with a history of cocaine use presented with
headache, mucopurulent sinusitis, and hypertension. The patient had
had microscopic hematuria 6 months previously. He had no history of
intravenous drug use. On physical examination, the blood pressure was
160/100mm Hg. A left facial paralysis (thought to be an idiopathic Bell's
palsy) was present. The lungs were clear to auscultation, and the
cardiac examination was normal. He had no hepatosplenomegaly and
no edema. The serum creatinine was 4.1 mg/dl; BUN, 35 mg/dl;
albumin, 2.9 g/dl; glucose, 130 mg/dl; sodium, 138 mEq/liter; potassium,
4.4 mEq/liter; chloride, 97 mEq/liter; and bicarbonate, 27 mEq/liter.
Urinalysis revealed a pH of 6.5; specific gravity, 1.020; 4+ protein; 2+
blood; 10—20 erythrocytes/high-power field; and erythrocyte and gran-
ular casts. A 24-hour urine collection contained 10 g protein, and the
creatinine clearance was 15 mI/mm. Other laboratory studies included
C3, 118 mg/dl (normal, 60—150 mg/dl); C4, 44 mg/dl (normal, 12—40
mg/dl); ANA, negative; ANCA, negative; rheumatoid factor, negative;
anti-GBM antibodies, negative; and negative hepatitis B virus and
hepatitis C virus serologies.
A renal biopsy was performed. Light microscopy revealed 10 glomer-
uli per section, of which one-half demonstrated global glomeruloscle-
rosis. Mesangial cell proliferation, with an increase in both cellularity
and matrix, was present in intact glomeruli. Focal cellular crescents
were present in 2 glomeruli. Coincident extensive tubular atrophy was
associated with interstitial fibrosis and a nonspecific mononuclear cell
infiltrate; there was no evidence of vasculitis. Immunofluorescence
demonstrated 3+ IgA deposition in the mesangium with no significant
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glomerular staining for IgG, 1gM, C3, fibrinogen, or albumin. Electron
microscopy disclosed prominent expansion of the mesangium due to
increased matrix, and a mild increase in mesangial cellularity. Small
electron-dense deposits were seen in the mesangium; focal effacement
of epithelial foot processes also was noted. A diagnosis of IgA nephrop-
athy, with features of focal crescent formation and extensive global
glomerulosclerosis, was made.
Discussion
DR. RICHARD J. JOHNSON (Physician, Division of Nephrol-
ogy, University of Washington Medical Center, and Associate
Professor of Medicine, University of Washington School of
Medicine, Seattle, Washington): This young man presented
with a history of cocaine use, nephrotic-range proteinuria, red
cell casts in the urine, and decreased renal function. Intrave-
nous drug abuse is associated with a variety of glomerular
diseases, including heroin nephropathy, HIV nephropathy,
hepatitis B or hepatitis C virus-associated glomerulonephritis,
polyarteritis nodosa, and amyloidosis. However, this patient
denied intravenous drug abuse and used cocaine solely by the
intranasal route. His renal biopsy showed mesangial prolifera-
tive nephritis due to IgA nephropathy. Although most cases of
IgA nephropathy are idiopathic, we can speculate that in this
case it was related to prolonged stimulation of IgA production
from cocaine-induced chronic suppurative sinusitis. (Perhaps
we should add this to the list of possible illicit drug-associated
nephropathies!)
The glomerulus is the target for many types of injury,
including immunologic (for example, immune-complex, T-cell,
or ANCA-mediated), hemodynamic (such as systemic or gb-
merular hypertension), metabolic (such as diabetes), "athero-
sclerotic" (for example, as a consequence of intraglomerular
lipid accumulation), infiltrative (such as amyloid) and toxic
causes (such as snake venoms). The type and duration of the
insult are extremely important to the overall prognosis, but the
central thesis of my presentation today is that the glomerular
lipid response to injury is not passive, but rather contributes to
disease resolution, chronicity, or progression.
This is not to say that the glomerular response to injury
differs in every individual. Rather, several basic responses
appear common, especially the responses of the injured mesan-
gial cell. These include: (1) cell proliferation and/or hypertro-
phy; (2) expression of new antigens, resulting in an "activated"
phenotype; and (3) extracellular matrix deposition. Intertwined
with these processes are mechanisms that restore the original
gbomerular architecture to normal, a process that I will refer to
as the reparation (restoration) phase. As Border has empha-
sized, if the response to gbomerular wounding is exuberant,
excess scarring can occur that may be analogous to keloid
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Fig. 1. Cellular proliferation in
glomerulonephritis. Normal rat glomerulus (a)
and glomerulus from a rat with mesangial
proliferative nephritis (b) immunostained for
PCNA, a nuclear protein expressed by
proliferating cells. Numerous proliferating
cells are observed within the diseased
glomerulus. (x 400, immunoperoxidase.)
formation seen with skin wounding (Border W, personal com-
munication). Some proliferation and extracellular matrix depo-
sition probably is necessary for healing of the injured glomeru-
lus, however. Thus the interaction of all these processes
ultimately determines whether the glomerulus will recover or
die. I will now discuss the basic glomerular responses to injury,
particularly of the mesangial cell, and will emphasize work
performed in our laboratory.
Cell proliferation
Mesangial hypercellularity is a characteristic feature of sev-
eral glomerular diseases, especially idiopathic IgA nephropa-
thy, membranoproliferative nephritis, and lupus nephritis. In-
deed, mesangial hypercellularity was a prominent feature in the
patient presented today. Although it has frequently been as-
sumed that hypercellularity in mesangial areas is equivalent to
mesangial cell proliferation, a contribution by infiltrating mac-
rophages or other mononuclear cells has not been excluded
consistently. That mesangial cell proliferation is in fact a major
feature of glomerular injury was first documented in 1977 by
Bradfield and colleagues, who demonstrated 3H-thymidine up-
take by glomerular cells in the Habu snake venom model of
mesangial proliferative nephritis [1]. Utilizing a clever experi-
mental design involving kidney transplantation, the authors
showed that the mesangial hypercellularity resulted from cell
proliferation within the glomerulus and not from the localization
of migrating mononuclear cells from the bone marrow [1].
We have studied the rat model of mesangial proliferative
nephritis induced by complement-fixing antibody to the Thy 1
antigen present on the mesangial cell membrane [2—6]. This
model is characterized by an acute complement-dependent
mesangiolysis that peaks in the first 24 hours and that results in
an almost complete loss of mesangial cells and mesangial matrix
[2—8]. The cells in mesangial areas then increase markedly, with
excess deposition of mesangial matrix resulting in a hypercel-
lular, lobular lesion reminiscent of active mesangial prolifera-
tive nephritis in humans [2—8]. Subsequently the number of
mesangial cells and the amount of matrix return to normal
during a reparation phase [6].
To demonstrate that mesangial cell proliferation occurs in the
Thy 1 model, we immunostained tissue for the proliferating cell
nuclear antigen (PCNA), a nuclear protein [9] that is markedly
upregulated from late G 1 through the M phase of the cell cycle.
A marked increase in PCNA-positive cells was documented in
glomeruli 2 to 7 days following administration of the anti-Thy 1
antibody [2—6] (Fig. 1). Double immunolabeling demonstrated
that the vast majority of the PCNA-positive cells lacked leuko-
cyte markers (that is, the common leukocyte antigen present in
all leukocytes, and the ED-i antigen present in monocytes and
macrophages) but did stain for Thy 1 (a mesangial cell marker)
and a-smooth muscle actin (a smooth-muscle-cell-associated
protein) [2—6, 10]. These observations demonstrated that me-
sangial cell proliferation was in fact taking place.
Similar types of studies utilizing PCNA expression or 3H-
thymidine uptake have confirmed that glomerular cell prolifer-
ation occurs in other experimental models of renal disease,
including progressive glomerulosclerosis in the remnant kidney
model [ii], experimental focal sclerosis induced by aminonu-
cleoside [12], murine and rat models of lupus nephritis [13, 14],
streptozotocin-induced diabetes mellitus [15, 16], and in mice
transgenic for growth hormone [17]. We also recently demon-
strated an increase in PCNA-positive glomerular cells in a
variety of human glomerular diseases in which the mesangium
is involved, including some cases of diabetic nephropathy [18].
In many of these studies, double immunolabeling confirmed
that the majority of the proliferating cells were not of hematog-
enous origin, and thus probably were endogenous glomerular
(and probably mesangial) cells [11, 15, 18]. Cell proliferation is
therefore a prominent response of the glomerular mesangium to
injury. What are the potential cellular or humoral mediators of
this response?
Platelets. Platelets are likely major mediators of glomerular
cell, and especially mesangial cell, proliferation. First, platelets
are equipped with an arsenal of growth factors in their a and
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dense granules, which they can release on activation. One
important growth factor released by platelets, platelet-derived
growth factor (PDGF), is responsible for much of the mitoge-
nicity of serum [191. However, platelets also release numerous
other growth factors, including basic fibroblast growth factor
(bFGF), transforming growth factor a (TGF-a), TGF-/3, epider-
ma! growth factor (EGF), hepatocyte growth factor (HGF), the
insulin-like growth factors I and II (IGF-l, IGF-2), platelet-
derived endothelial cell growth factor, and serotonin and ade-
nine nucleotides [20—25, reviewed in 26]. Activated platelets
also express interleukin 1 (IL- 1) on their cell surface [27]. Most
of these growth factors are known to stimulate mesangial cell
proliferation in vitro [28, 29, reviewed in 30].
Activated platelets or platelet antigens can be localized in
glomeruli in many types of experimental and human prolifera-
tive glomerulonephritis [3, 11, 31—34]. In diseases such as
mesangial proliferative and membranoproliferative glomerulo-
nephritis, platelet activation can be demonstrated, as shown by
decreased platelet survival, the presence of platelet release
products in plasma (for example, serotonin), and circulating
platelets with reduced granule contents [35—37]. In several
experimental diseases, the glomerular platelet accumulation
precedes the development of glomerular hypercellularity [3, 11,
33, 34, 38—40]. For example, we demonstrated a marked influx
of platelets that precedes overt glomerular cell proliferation in 4
experimental disease models [3, 11, 33, 34]. In these models the
proliferating cells appeared to be mesangial cells [2, lii and
glomerular endothelial cells [33, and personal observations].
The strongest evidence supporting a role for platelets in
glomerular cell proliferation is from studies in which depletion
of platelets with specific antibodies reduced mesangial cell
proliferation in experimental models of mesangial proliferative
nephritis. Cattell first demonstrated this reduction in the habu
snake venom model [41], and we later duplicated the finding in
the Thy 1 model [2]. Anti-platelet agents also reduce mesangial
cell proliferation in the habu model [42, 43]. Certain anti-
platelet agents, such as aspirin, however, do not effectively
block the platelet release reaction on exposure to collagen [44].
Perhaps this is one reason why it has been difficult to show
efficacy of aspirin and dipyridamole in the clinical management
of membranoproliferative nephritis [45].
Monocytesimacrophages. Macrophages also contain a vari-
ety of growth factors, including PDGF, TGF-/3, IL-i, TNF-a,
IL-6, and bFGF [reviewed in 46]. Some reports note that many
of these growth factors stimulate mesangial cell proliferation in
vitro [47—53, reviewed in 30], whereas other studies have found
some of these same growth factors inhibitory [54, 55]; activated
macrophages also release nitric oxide [56], a potent inhibitor of
mesangial cell proliferation [57].
The in-vivo evidence that macrophages mediate mesangial
cell proliferation is inconclusive. Macrophages are present in
glomeruli in a variety of experimental and human diseases in
which mesangial cell proliferation has been demonstrated,
including mesangial proliferative nephritis, membranoprolifer-
ative nephritis, focal segmental sclerosis, and diabetes [5, 15,
58—62]. In some of these experimental models, however, the
glomerular macrophage infiltration occurs after the onset of
mesangial cell proliferation [11, 15, 59, 63]. In some experimen-
tal models, a reduction in the glomerular macrophage accumu-
lation, either by anti-macrophage serum [64, 65], irradiation
[66], or by treatment with the IL-I receptor antagonist [67], also
reduced the glomerular hypercellularity, but it is not known to
what extent this reduction was due to the depletion of circulat-
ing leukocytes. In aminonucleoside nephrosis, maneuvers that
increased glomerular macrophage accumulation (for example,
high-cholesterol diet) increased glomerular cell proliferation (as
measured by PCNA expression); conversely, measures that
reduced glomerular macrophage accumulation (essential fatty
acid deficiency) reduced cell proliferation [68]. But it is possible
that these dietary maneuvers also could affect the mesangial cell
directly. Finally, one study has reported a decrease in the
mesangial cell outgrowth from isolated glomeruli of rats with
nephrotoxic nephritis after treatment with an anti-macrophage
antibody [69].
Growth factors. Studies have examined the role of several
specific growth factors in mediating mesangial cell proliferation
in glomerulonephritis. I will summarize these results.
bFGF. A growth factor present in platelets, macrophages,
mesangial cells, and glomerular epithelial cells, bFGF may well
have an important role in mesangial proliferative disease. First,
bFGF stimulates mesangial cell proliferation in vitro and also
stimulates mesangial cells to produce other growth factors such
as PDGF [53, 70]. While in our laboratory, Floege demon-
strated that intravenous infusion of bFGF in rats induces
mesangial cell proliferation in vivo, although the rats must first
receive a subnephritogenic dose of anti-Thy 1 antibody [53, 71].
In the Thy 1 model of mesangial proliferative nephritis, mesan-
gial cells release their bFGF during the initial, mesangiolytic
phase [53]. This observation has suggested to us that bFGF,
released from lysed mesangial cells, and also possibly from
infiltrating macrophages or platelets, might mediate the initial
phase of mesangial cell proliferation in this model. This possibly
is analogous to the carotid angioplasty model, in which bFGF
mediates the initial smooth muscle cell replication [72].
PDGF. First described in 1974 [19], PDGF is a 28—32 kD,
highly cationic protein that contains two chains (A- and B-) that
combine to form three different isoforms (AA, AB, and BB).
The PDGF receptor (PDGF-R) also consists of an a- and
/3-subunit that also forms three different isoforms. Growth
factors PDGF-BB and PDGF-AB can bind all 3 PDGF-R
isoforms, although PDGF-AB binds the /3/3 PDGF-R with low
affinity [73, 74]. In contrast, PDGF-AA only binds aa PDGF-R
[73].
Strong evidence supports a role for PDGF in mesangial cell
proliferation [reviewed in 75—77]. First, PDGF is a major
mitogen for mesangial cells in culture [47, 48], and also induces
mesangial cells to produce growth factors, including IL-i,
TGF-/3, and PDGF itself [70, 78, 79]. A recent report suggests
that mesangial cells grown in a 3-D type-I collagen gel lose their
PDGF-R /3-subunit and become unresponsive to PDGF [80];
this finding suggests that mesangial cells in vivo might be
similarly unresponsive. Both rat and human mesangial cells
express PDGF-R /3-subunit in vivo, however [5, 81]. Further-
more, infusion of PDGF into normal rats results in a substantial
proliferation of mesangial cells [71]. Isaka et al transfected rat
glomeruli in vivo with a human PDGF B-chain gene [82];
glomeruli from these rats demonstrated a significant cell prolif-
eration in mesangial areas in conjunction with a mild increase in
mesangial matrix. These studies demonstrate that PDGF is a
functional mitogen for mesangial cells both in vitro and in vivo.
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PDGF and PDGF receptors also are expressed both in
experimental and human glomerulonephritis in which mesangial
cell proliferation occurs [5, 13, 15, 16, 83—89, reviewed in
75—77]. Following an initial report that PDGF could be localized
in glomeruli in 25% of patients with diffuse proliferative lupus
nephritis [83], our group and Gesualdo et al simultaneously
reported that PDGF is upregulated in glomeruli in experimental
mesangial proliferative nephritis [5, 84]. In the Thy I model, an
increase in both PDGF mRNA (A- and B-chain) and PDGF
protein (B chain) was demonstrated in glomeruli. The upregu-
lated expression correlated with mesangial cell proliferation and
was inhibited if the cell proliferation was prevented by comple-
ment or platelet depletion [5, 85]. The source of the PDGF
might be either infiltrating cells (for example, platelets or
macrophages), or the endogenous glomerular cells themselves,
as all of these cell types can release PDGF [reviewed in 77].
However, the observation that the distribution of the PDGF
B-chain mRNA appeared to be mesangial by in-situ hybridiza-
tion [85], and that, by immunostaining, the majority of the
PDGF-positive cells also expressed the smooth muscle cell
marker, a-smooth muscle actin [5], strongly suggested that the
major source of the PDGF was the mesangial cell. This finding,
coupled with the observation that the upregulated expression of
the PDGF-R also was in a mesangial distribution, is evidence
that PDGF was acting as an autoenne growth factor, a phenom-
enon previously shown in vitro [70].
Expression of PDGF has been reported in many experimental
diseases in which mesangial cell proliferation occurs, including
the remnant kidney model [11], chronic aminonucleoside ne-
phrosis [12], streptozotocin-induced diabetes [15, 16], habu
snake venom nephritis [86], and munne lupus nephritis [13].
This factor is also highly expressed in mesangial regions in IgA
nephropathy and mesangial proliferative nephritis in humans
[84, 87]. I believe that the strongest evidence that PDGF is a
mediator of mesangial cell proliferation in nephritis is our
observation that inhibition of PDGF in vivo with a neutralizing
antibody significantly reduced the mesangial cell proliferation at
day 4 in the Thy 1 model [90]. The fact that no inhibition of
proliferation occurred at day 2, however, suggests that other
growth factors (for example, bFGF) are involved in the initial
proliferative response.
Other growth factors. Other growth factors and vasoactive
substances mediate mesangial cell proliferation in vitro [re-
viewed in 30], and increasing evidence implicates a role for
some of these cytokines in disease. For example, mice trans-
genic for growth hormone develop a mesangial proliferative
oephritis [17, 91], and similar lesions have been reported for
mice transgenic for IL-6, SV-40, and HIV [92—94]. Rats in
which kidneys have been transfected with the human TGF-13
gene develop a mild glomerular cell proliferation [82]. Other
ytokines, such as IL-i, IL-6, TNF-a, and endothelin also are
expressed in a variety of experimental diseases in which me-
;angial cell proliferation is present [52, 95—99]. Recently Lan et
al reported that treatment with the IL-i receptor antagonist
lecreases glomerular hypercellularity in rats with anti-GBM
ephritis [67]. It is not known whether the effect was due to a
reduction in the number of infiltrating leukocytes or of prolif-
rating glomerular cells, however.
Other mechanisms. Finally, other factors likely influence cell
proliferation, including extracellular matrix [100, 101], pros-
tanoids [102, 1031, and intraglomerular lipid accumulation [104].
For example, a role for the mevalonate pathway in mesangial
cell proliferation is suggested by the finding that inhibitors of
mevalonate synthesis reduce mesangial cell proliferation in
vitro in response to serum [105] and PDGF [106] and reduce
mesangial hypercellularity in an experimental model of glomer-
ulosclerosis [1071.
Cell phenotype changes
Glomerular injury is also characterized by phenotypic
changes of the glomerular cell populations, especially of the
mesangial cell. In a number of experimental models in which
the mesangial cell is injured, including models of mesangial
proliferative nephritis (for example, Thy 1 and habu snake
venom models), lupus nephritis (for example, concanavalin
Alanti-concanavalin A nephritis), experimental diabetes melli-
tus, and progressive glomerulosclerosis (that is, the remnant
kidney model), we have observed that the mesangial cell
expresses a vascular smooth-muscle-cell-associated protein,
a-smooth muscle actin [4, 11, 15] (Fig. 2). This protein is also
expressed in a variety of human glomerular diseases associated
with mesangial cell injury [181. Other cytoskeletal proteins
associated with cell movement or contraction are also upregu-
lated in experimental mesangial proliferative nephritis, includ-
ing vimentin, desmin, and moesin [4, and personal observations].
De-novo synthesis and mesangial deposition of interstitial col-
lagens (that is, type-I collagen) also have been demonstrated [6,
59]. The observation that the mesangial cell is expressing both
smooth muscle (that is, a-smooth muscle actin) and fibroblast
(that is, type-I collagen)-associated proteins suggests that the
activated mesangial cell is acquiring characteristics of a "myo-
fibroblast" [108].
The mechanism mediating the phenotype change to a "myo-
fibroblast" remains unknown. The original observation that this
phenotypic change was often expressed by proliferating mesan-
gial cells suggested that this change was intricately linked to cell
proliferation [4]. We subsequently showed, however, that
a-smooth muscle actin is expressed by mesangial cells in rats
made hypertensive with angiotensin II, despite minimal mesan-
gial cell proliferation [109]. In addition, rats infused with PDGF
develop mesangial cell proliferation but do not express
a-smooth muscle actin or type-I collagen [71]. One possibility is
that these phenotypic changes are the consequence of glomer-
ular hypertension; another possibility is mediation by other
cytokines such as TGF-/3.
Myofibroblasts in other tissues are involved in both the
matrix deposition and wound contraction processes of wound
healing [110, 111]. Although the functional consequences of the
phenotypic modulation of the mesangial cell are not known, the
expression of a-smooth muscle actin by hepatic lipocytes in
experimental cirrhosis is associated with increased contractility
[ill].
Finally, some of the phenotypic changes might involve up-
regulated or de-novo expression of cell-membrane-associated
antigens, such as PDGF-R and the nerve growth factor receptor
[5, 112]. Indeed, one wonders whether the increased rejection
rate observed in kidneys with IgA nephropathy that were
inadvertently transplanted [1131 is due to the expression of
de-novo or normally sequestered antigens.
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Fig. 2. Phenotypic changes in
glomerulonephritis. Normal rat glomerulus (a)
and glomerulus from a rat with mesangial
proliferative nephritis (b) immunostained for
a-smooth muscle actin, the principal actin
isoform of vascular smooth muscle. In normal
kidney, a-smooth muscle actin is present in
smooth muscle cells in arterioles, but it is
absent in the glomerulus. In contrast, in rats
with mesangial proliferative nephritis, a
dramatic expression of a-smooth muscle actin
by mesangial cells is observed. (x 400,
immunoperoxidase.)
Fig. 3. Extracellular matrix expression in
glomerulonephritis. Normal rat glomerulus (a)
and glomerulus from a rat with mesangial
proliferative nephritis (b) immunostained for
laminin. A marked mesangial expression of
laminin is noted in the diseased glomerulus.
(x 400, immunoperoxidase.)
Extracellular matrix deposition
The third major characteristic of glomerular injury is in-
creased deposition of extracellular matrix. This phenomenon is
particularly common in diseases affecting the mesangium, as in
the patient presented today (that is, IgA nephropathy), and in
mesangial proliferative nephritis, membranoproliferative gb-
merulonephntis, and diabetic nephropathy. Various studies
have examined the components of the extracellular matrix
involved, In the Thy 1 model, for example, mesangial deposi-
tion of most extracellular matrix proteins is increased, including
type-IV collagen, laminin, fibronectin, heparan sulfate proteo-
glycan, and entactin/nidogen [6] (Fig. 3). Some of the increased
deposition in this model and other diseases is due to increased
synthesis of these components [6, 59, 114—117], but there also
might be inhibition of matrix-degrading proteinases that is due
to upregulation of the tissue inhibitor of metalboproteinases
(TIMP) [1181 or of plasminogen activator inhibitor (PAl) [119].
What are the mechanisms responsible for these changes?
The macrooha2e might play an important role in extracellular
matrix expansion. Infiltration of macrophages is seen both in
experimental [59, 68] and human [61] focal gbomeruboscierosis.
In experimental models of progressive glomeruloscierosis (that
is, the remnant kidney model) and in diabetes mellitus, the
glomerular macrophage number correlates with the degree of
sclerosis and matrix expansion present [15, 59]. In the Thy I
model, treatment with y-interferon doubled both the glomerular
macrophage number and the glomerular type-IV collagen
mRNA (personal observations). This approach was associated
with an increase in TGF-/3 mRNA, which is known to be
expressed by activated macrophages, and which is likely to
have a role in matrix expansion. Although all this evidence is
consistent with a pathogenetic role for the macrophage, the data
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Table 1. Normal mechanisms of resolution (glomerular healing)
Resolution of cell proliferation
Resolution of glomerular hypercellularity
Efflux of leukocytes
Matrix remodeling
Glomerular capillary repair (? angiogenesis)
remain correlative at best, and proof will have to await specific
macrophage-depletion studies.
Strong evidence supports a role for TGF-J3 in the extracellu-
lar matrix expansion that accompanies glomerular disease.
First, TGF-3 stimulates collagen, fibronectin, proteoglycan,
and PAT synthesis in cultured mesangial cells [49, 119, 120].
Second, TGF-/3 is expressed in a variety of experimental and
human glomerular diseases in which extracellular matrix depo-
sition is evident [13, 16, 12 1—1251. Isaka and coworkers recently
reported that the transfection of the human TGF-/3 gene into rat
kidneys markedly expands extracellular matrix [82]. Most im-
portant, however, are the studies by Border et a!, in which the
inhibition of TGF-/3 by neutralizing antibody [126], decorin
[1271, or low-protein diet [1281 prevented matrix expansion in
the Thy 1 model.
Other growth factors are likely also involved. As I mentioned
earlier, infusion of PDGF [71] or transfection into rat kidneys of
the PDGF B-chain gene [821 results in marked mesangial cell
proliferation and mild matrix expansion. Inhibition of PDGF in
the Thy 1 model also significantly reduced the matrix expansion
by 20% to 40% [90]. Recent studies using various inhibitors also
implicate endothelin [129], platelet-activating factor [130], IL-i
[67], and IL-6 [131] in the matrix expansion that accompanies
experimental glomerular disease.
Normal mechanisms of resolution
Despite the major mesangial cell proliferation and matrix
expansion that occur acutely in the Thy 1 model, a particularly
exciting observation is that the glomeruli recover. Only minor
histologic abnormalities are present at 6 weeks [6]. Thus normal
mechanisms must be responsible for glomerular healing in this
model as in most patients with acute, poststreptococcal glomer-
ulonephritis. I will now discuss this "reparation phase" (Table
1).
Earlier I said that mesangial cell proliferation is associated
with upregulated expression of both PDGF and PDGF-R by the
mesangial cell, which in turn allows for an autocrine-driven
pathway that theoretically should continue unabated. There-
fore, some factor must be released to stop this cycle. Factors
shown to inhibit mesangial cell proliferation in vitro include
TGF-p, hepann and heparan sulfate proteoglycan, nitric oxide,
atrial natriuretic peptide, y-interferon, and a small nonprotein
inhibitor produced by cultured mesangial cells [49, 50, 57,
132—136]. Some of these factors are expressed in the Thy 1
model, as well as in other models of glomerular disease [6, 56,
121—125]. Another potential candidate is osteonectin (SPARC),
a 43 kD glycoprotein that inhibits proliferation of a variety of
cell types in culture [137—139], and which specifically com-
plexes with PDGF, thereby preventing PDGF from binding to
its receptor [140]. Ongoing studies in our laboratory have
shown that both SPARC mRNA and protein are upregulated in
glomeruli in the Thy 1 model (unpublished data). A synthetic
peptide fragment of SPARC is also a potent inhibitor of mesan-
gial cell proliferation in vitro (personal observations). Further
studies are necessary to determine whether SPARC has a major
role in regulating mesangial cell proliferation in human disease.
In the Thy 1 model, the mesangial cell number doubles by day
5, yet returns to normal by 4 to 6 weeks [4—6]. How does the
glomerular hypercellularity resolve? One possibility is that it
involves apoptosis, or programmed cell death [reviewed in 141].
Mesangial cells undergo apoptosis after serum deprivation in
vitro, and apoptotic cells can also be found in the Thy 1 model
(Baker A, Johnson R, Savill J, unpublished data). Further
studies are ongoing to identify the nature of these apoptotic
cells and their mechanisms of clearance.
During glomerular inflammation, leukocytes, particularly
macrophages, often accumulate. In the Thy 1 model, however,
the leukocyte infiltration resolves by day 21. We need to study
the mechanisms for the progressive decrease in leukocyte
number. Could it be apoptosis, or is there an efflux of leuko-
cytes via the circulation or lymph? Evidence for the latter
possibility recently was reported by Lan et al in a model of
anti-GBM nephritis [142, 143].
What mechanisms are responsible for matrix resorption and
remodeling? In collaboration with D. Lovett, we recently
showed that mesangial cells increase their production of a 72 kD
type-TV collagenase in the Thy 1 model [144]. Although the
release of type-TV collagenase might contribute to some of the
capillary wall injury that occurs in this model [144], the release
of this proteinase also might aid in the remodeling of the
expanded mesangial matrix. Other matrix-degrading proteases
probably are also released during the reparation phase, includ-
ing other metalloproteinases and plasmin.
Finally, capillaries might be repaired during the restoration
phase, especially in areas of mesangiolysis where ballooning
microaneurysms have disrupted endothelial cell integrity. Pre-
liminary studies in the Thy 1 model suggest that some endothe-
hal cell migration, proliferation, or both occur during reparation
of the microaneurysms (personal observations).
Conclusion
There appear to be several basic responses of the glomerulus
to injury. A prominent response, mesangial cell proliferation
with the development of mesangial hypercellularity, occurs
with almost any disease that involves the mesangium, including
diabetic nephropathy or amyloidosis [18]. Although multiple
factors probably mediate cell proliferation, the two best-estab-
lished mediators are platelets and the growth factor PDGF. It is
still not clear, however, that blocking the proliferative response
is necessarily of long-term benefit in humans with mesangial
glomerulonephritis. Certainly some mesangial cell proliferation
must be a healthy response in situations in which mesangial
cells have been injured or lost.
Another basic response appears to involve changes in gb-
merular cell phenotype. For the mesangial cell, this response
involves transformation into a "myofibroblast"-like cell. This
phenotype change results in the ability of these cells to secrete
interstitial collagens as well as to express contractile proteins.
Like the myofibroblast in skin wounds, the mesangial "myofi-
broblast" likely has an important role in glomerular scarring
and fibrosis.
The glomerulus' third basic response to injury is increased
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deposition of extracellular matrix. This reaction appears to be
due both to increased synthesis as well as to decreased degra-
dation of various matrix components. The major mediators
implicated include macrophages and TGF-/3 and, to a lesser
extent, PDGF.
Counteracting all these inflammatory processes are mecha-
nisms that restore glomerular architecture to normal. These
reparative mechanisms, which include measures to inhibit cell
proliferation, reduce glomerular hypercellularity, remodel the
mesangial matrix, and stimulate capillary repair, have been
studied only minimally but could prove important in determin-
ing the overall outcome of a particular disease.
Why does glomerular disease progress in some patients and
not in others? The type and duration of the insult is obviously of
major importance. For example, in rats injected with one dose
of anti-Thy 1 antibody, the glomerular disease resolves, but if
multiple doses are administered, a progressive and irreversible
glomerulosclerosis develops [145, 146]. Why do repeated doses
cause progressive disease? Is there just greater cell prolifera-
tion, phenotypic changes, and extracellular matrix deposition,
or are the normal resolution mechanisms altered? Are there
ways to change the course of a disease to allow normal
glomerular healing, as opposed to the relentless progression to
end-stage renal disease? Our understanding of the glomerular
response to injury is still in its infancy, and much should be
learned in the years to come.
Questions and answers
DR. NIcoLAos E. MADLAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): De-
spite the title of your presentation, "The glomerular response to
injury: Progression or resolution," it appeared to me that your
talk was almost exclusively devoted to the mesangial cell's
response to injury. Are any of these processes operative in
other glomerular cell populations?
DR. JOHNSON: My presentation emphasized the mesangial
cell's response to injury, as this is the cell population studied
the most in disease. However, very similar responses can be
seen with other glomerular cell populations. For example, my
collaborators, J. Floege and W. Couser, have performed studies
in the passive Heymann model of membranous nephropathy, in
which the glomerular epithelial cell is the target of antibody-
mediated and complement-mediated attack. In this model,
visceral glomerular epithelial cells express proliferation-associ-
ated antigens (that is, PCNA) and undergo mitoses; these
changes suggest actual cell proliferation or the development of
polyploidy [147]. PDGF B-chain mRNA and protein also are
expressed, although the significance of this remains uncertain
because these cells lack PDGF-R [147]. The injury is associated
with a phenotype change in which the cells upregulate their
expression for SPARC as well as the muscle-associated inter-
mediate filament protein, desmin [148]. An increase in laminin
and s-laminin deposition also occurs in the capillary wall in a
related model [149]. Similar changes, including cell proliferation
and PDGF expression, occur in parietal epithelial cells in a
variety of experiments and human glomerular diseases (person-
al observations). It seems likely that a similar array of re-
sponses occurs in the glomerular endothelial cell as well, but
these responses have not yet been carefully studied.
DR. DAVID KATES (Renal Fellow, University of Washington
Medical Center, Seattle, Washington): Do you believe that
these cellular responses are unique to the glomerulus, or are
these features observed with cellular injury in general?
DR. JOHNSON: Many of the processes we are studying have
been observed in other organ systems. For example, PDGF
expression has been observed in skin wounding, atherosclero-
sis, interstitial pneumonitis, and rheumatoid synovium [150—
153]. In experimental cirrhosis, the lipocyte undergoes a phe-
notypic change in which it expresses a-smooth muscle actin and
interstitial collagens [154, 155]. Similar changes occur with the
interstitial fibroblast in bleomycin-mediated lung injury [156]. In
addition, many of the findings observed with vascular smooth
muscle injury after angioplasty have similarities with mesangial
cell injury [reviewed in 157]. I suspect, however, that there also
will be some differences in the cellular response between organ
systems.
DR. MADIAS: Could you tell us which human disease the
anti-Thy 1 model most resembles? Also, are there any other
maneuvers exclusive of repetitive injections of anti-Thy 1
antibody that can make this model enter a chronic phase?
DR. JOHNSON: Although the Thy 1 antigen is present in
human kidneys [158], it is not known whether a human anti-Thy
1 disease exists. Some patients with IgA nephropathy do have
anti-mesangial cell IgG antibodies, however [159]. Mesangioly-
sis, which is a characteristic feature of the anti-Thy 1 model, is
also common in a variety of glomerular diseases, including
membranoproliferative glomerulonephritis and diabetes [160].
Rare patients have had recurrent mesangiolysis that resembles
anti-Thy 1 disease in humans (Dowling J, Royal Melbourne
Hospital, personal communication).
The importance of the Thy 1 model is not that it is an exact
model of a specific human disease, but rather that it demon-
strates the biologic consequences of immune mesangial injury.
Thus, we have demonstrated that the proliferative and pheno-
typic changes that the mesangial cell undergoes in the anti-Thy
1 model also occur in other experimental models [11, 15] as well
as in human disease [18].
In relation to the second question, repetitive injections of
anti-Thy 1 antibody can induce glomerulosclerosis [145], which
can be accelerated if a unilateral nephrectomy is also performed
[144]. I am not aware of any other manipulations that can
induce this disease to become chronic, however.
DR. EDMUND LEWIS (Chief, Division of Nephrology, Rush-
Presbyterian-St. Lakes Medical Center, Chicago, Illinois): Will
modulation of the initial cell proliferation alter the autocrine
phase of the anti-Thy 1 model, and does this imply any
importance to inhibiting platelet activation? Also, would you
consider using anti-platelet agents in human forms of mesangial
proliferative glomerulonephritis (for example, IgA nephropa-
thy) to limit mesangial cell proliferation and activation?
DR. JOHNSON: Platelets appear to play an important role in
mesangial cell proliferation in the Thy 1 model. Platelets
infiltrate the glomeruli early, peaking at 8 hours alter disease
induction [3]. Depletion of platelets with anti-platelet antibody
significantly reduces the mesangial cell proliferation at day 3
[2]. Inhibition of mesangial cell proliferation by platelet deple-
tion also inhibits mesangial cell PDGF expression [5]; this
finding suggests that modulation of the initial proliferative phase
can alter the PDGF-derived autocrine-mediated amplification.
Although these studies [2—5] suggest that anti-platelet agents
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might be useful in human mesangial proliferative nephritis,
clinical trials have had conflicting results [161—163]. One prob-
lem is that certain anti-platelet agents, such as aspirin, do not
block the platelet-release reaction or the adherence of platelets
to collagen [44]. Aspirin also does not block the platelet release
of lipoxygenase products, which can augment neutrophil func-
tion [164]. Thus, whereas aspirin does block platelet-thrombi
formation, it might not be the best agent for treating glomeru-
lonephritis.
One anti-platelet agent that does carry some promise is
trapidil. In addition to being an anti-platelet agent, trapidil also
blocks PDGF binding to the PDGF-R and inhibits mesangial cell
proliferation in response to PDGF in vitro [165, 166]. Recent
studies have shown that trapidil can reduce hypercellularity and
mesangial cell proliferation in the Thy 1 model [166].
DR. WILLIAM G. COUSER (Professor of Medicine, University
of Washington Medical Center): You focused primarily on the
glomerular response to injury and its role in progressive renal
disease, but much evidence suggests that it is the degree of
interstitial disease that determines the overall prognosis [167].
Do you have any thoughts about how processes in the glomeruli
can affect the interstitial compartment?
DR. JOHNSON: Evidence suggests that with glomerular injury,
many cytokines and chemotactic factors are released; these
then could either diffuse directly out of the glomerulus, exit via
the efferent arteriole, or pass into the urine. Among many
potential mediators, two prime candidates are IL-l [67] and a
lipid chemotactic factor [168]. These factors might induce
surrounding tubules, peritubular interstitial cells, and capillary
endothelial cells to express leukocyte adherence proteins such
as ICAM-1 and VCAM [169—171], which could attract leuko-
cytes and induce tubular injury. We recently implicated another
leukocyte adherence protein, osteopontin, in tubulo-interstitial
disease [172, 173]. In collaboration with C. Giachelli and S.
Schwartz, we have shown that, in several models of glomerular
disease, tubular cells express osteopontin mRNA and protein.
Osteopontin initially concentrates around glomeruli and local-
izes with the macrophage infiltrate [173]. Future studies will be
necessary to determine whether osteopontin is simply a marker
of tubular injury, or whether it actually mediates the leukocyte
accumulation that occurs.
DR. KAROL BOMSZTYK (Associate Professor of Medicine,
University of Washington Medical Center): Do you believe that
multiple growth factors and cytokines are involved in your
disease model and, if so, what does this imply for treatment?
DR. JOHNSON: I suspect that many growth factors are in-
volved in this disease. One wonders whether they are all
intricately interconnected and interwoven, much like a Gordian
knot. Is inhibition of but one growth factor like cutting a single
strand, allowing the whole thing to fall apart? I believe that this
probably is not the case, and that each growth factor will have
a more-or-less specific role during a particular phase of the
disease. For example, in relation to the two currently best-
studied cytokines, namely PDGF and TGF-/3, I believe that the
data are consistent with PDGF having a role primarily in
proliferation, whereas the primary role of TGF-/3 relates to
extracellular matrix expansion.
DR. DENNIS L. ANDRESS (Associate Professor of Medicine,
University of Washington Medical Center): You suggested that
basic FGF might play a role in initiating mesangial cell prolif-
eration. Do you know whether bFGF stimulates PDGF expres-
sion in mesangial cells in vitro?
DR. JOHNSON: Yes, Silver et a! have shown that bFGF
stimulates PDGF mRNA and protein production in human
mesangial cells [70]. Interestingly, PDGF also stimulates bFGF
production in rat mesangial cells (Floege J, personal communi-
cation). We also have examined the effect of infusing bFGF on
glomerular PDGF mRNA and protein expression in vivo in
normal rats and in rats injected with subnephritogenic anti-Thy
1 antibody [71]. Interestingly, despite inducing mesangial cell
proliferation in rats with subnephritogenic anti-Thy 1 disease,
we were unable to induce PDGF expression [71]. As the
mesangial cell proliferation was only minor, it is possible that
the changes in PDGF expression were too mild to detect.
DR. ANDRESS: If in fact bFGF were mediating the initial
mesangial cell proliferation, would it be possible to block this
phase with heparin, which is known to bind bFGF [174]?
DR. JOHNSON: We recently published a study in which we
inhibited the initial phase of mesangial cell proliferation with
heparin [10]. However, it is important to realize that this
inhibition does not prove that the interaction is between heparin
and bFGF; heparin also affects other cytokines such as PDGF
[175] and might directly affect mesangial cell proliferation as
well [132].
DR. CHARLES ALPERS (Associate Professor of Pathology,
University of Washington Medical Center): As you are aware,
TGF- not only stimulates matrix production, but its activity is
regulated by physico-chemical interactions with the matrix
[176]. Do you have any information regarding matrix regulation
of either bFGF or PDGF?
DR. JoHNsoN: It is known that bFGF is bound with low
affinity to heparan sulfate proteoglycan in extracellular matrix,
where it can be released in active form by heparin or hepariti-
nases [174]. PDGF and PDGF-R also might be regulated in part
by extracellular matrix. Marx et al recently reported that rat
mesangial cells grown in a 3-dimensional type-I collagen gel
lose their PDGF-R and responsiveness to PDGF [80]. These
researchers suggested that this loss might have implications in
terms of how mesangial cells will respond in vivo because a
3-dimensional gel theoretically is a better model for the in-vivo
situation than is the standard 2-dimensional gel. However, rat
and human mesangial cells express the PDGF-R /3-subunit in
vivo [5, 81]. Furthermore, injection of PDGF into normal rats
[71], and in-vivo gene transfer of the PDGF-B chain into
glomeruli of normal rats [821, induces mesangial cell prolifera-
tion. This finding strongly suggests that mesangial cells express
functional PDGF-R in vivo.
DR. BOMSZTYK: Where do you think the main direction of
glomerular research is headed, and what techniques do you
envision will be useful in our understanding of the processes of
glomerular injury, and, consequently, for therapy?
DR. JOHNSON: I believe much is to be learned about the
intricate cytokine network that mediates both the progression
and resolution of glomerular disease. Careful study of the
expression of the cytokines with correlation to specific aspects
of disease are needed. Future studies will also likely include
specific inhibition of cytokines or cytokine receptors, infusion
of cytokines, or in-vivo gene transfer, and combinations of
these approaches.
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DR. MADIAS: Does the membrane-attack complex of comple-
ment (C5b-9) have a role in mesangial proliferative nephritis?
DR. JoHNsoN: Whether or not the membrane-attack complex
has a role in human mesangial proliferative nephritis can be
debated, although C5b-9 can be detected in the mesangium of
some patients [177]. However, there is indirect evidence that
C5b-9 mediates mesangiolysis in the anti-Thy 1 model, as it is
complement dependent and leukocyte and platelet independent
[2, 3, 7].
DR. BESSIE YOUNG (Senior Research Fellow, Division of
Nephrology, University of Washington Medical Center): You
described several processes, such as apoptosis and angiogene-
sis, which are known to be important in development. Can you
comment on any analogies between glomerular development
and glomerular disease?
DR. JOHNSON: Much of the glomerular response to injury
mimics aspects of glomerular development. Studies headed by
my collaborator, C. Alpers, have demonstrated that early
glomerular development is associated with PDGF B-chain and
PDGF-R 13-subunit expression [178]. The fetal mesangial cells
also express a-smooth muscle actin [178], nerve growth factor
receptor [112], and isoforms of cellular fibronectin [179]. These
proliferative and phenotypic markers also are seen both in
experimental and human mesangial proliferative nephritis [18,
112, 179, 180]. We are currently exploring the possibility that
angiogenesis and apoptosis occur in diseased glomeruli.
DR. MADIAS: Is your suggestion—that apoptosis is a compo-
nent of glomerular reparation—based on evidence of expression
of certain relevant genes?
DR. JOHNSON: Our studies on apoptosis during the resolution
of mesangial hypercellularity in glomerulonephntis have only
been initiated recently and are part of a collaborative study
done with Dr. John Savill's group in Nottingham, U.K. At this
time our evidence is based solely on the demonstration of
apoptotic bodies in the hypercellular lesions during the resolu-
tion phase. We would like to correlate this evidence with
Northern analysis or in-situ hybridization of genes known to be
connected with apoptosis, including transcriptional factors (for
example, c-myc and P53) and negative regulators of this process
(for example, the bcl-2 gene) [reviewed in 181]. This may be the
subject of future study.
DR. COUSER: I'd like to return to Dr. Bomsztyk's question.
Would you expand on the maneuvers that might have therapeu-
tic implications, such as anti-proliferative agents, anti-growth
factors, anti-cytokines, gene therapy, and anti-hemodynamic
agents. What do you think the future holds for the treatment of
diseases like IgA nephropathy?
DR. JOHNSON: I believe that the future treatment of human
glomerular diseases will involve maneuvers that affect all stages
of the glomerular disease. Thus, some maneuvers might be
directed at the causative agent. Examples of this type of
therapy now include the use of alpha interferon to treat hepatitis
B- or C-virus-associated glomerulonephritis [182, 183]. The use
of immunosuppressive agents to block the immunologic re-
sponse will also surely continue, although I suspect that new
agents specific for certain parts of the immune response will
become available. Finally, I believe that agents will be devel-
oped that will manipulate the glomerular response to facilitate
recovery. These could involve agents that block or stimulate
the growth factors that influence the proliferation, phenotype
change, and matrix expansion that occur with disease. Possible
agents include those that block various growth factors such as
PDGF, endothelin, IL-l, and TGF-f3. Some of these agents are
already available and have shown promise in experimental
disease models [67, 90, 126, 127, 129].
DR. MADIAS: Would you care to comment on the potential
use of HMG CoA reductase inhibitors in treating mesangial
proliferative nephritis?
DR. JOHNSON: There are some parallels between atheroscle-
rosis and glomerulosclerosis [reviewed in 184]. Of particular
interest is the observation that proliferation of mesangial cells in
vitro in response to serum or PDGF can be inhibited by
HMG-CoA reductase inhibitors, which block the formation of
mevalonate [105, 106]. These agents also reduce mesangial
hypercellularity in the glomerulosclerosis that develops in
obese Zucker rats [107]. Further studies are necessary to
determine whether these agents will be useful in other experi-
mental models and in human disease.
DR. CHRISTIAN HUGO (Research Fellow, Division of Ne-
phrology, University of Washington Medical Center): Concern-
ing the cell phenotype changes, recently it has been reported
that endothelin modulates myofibroblast-mediated tissue con-
traction [185]. Is there any evidence for a role for endothelin-l
in mediating myofibroblast tissue contraction in glomerular
disease?
DR. JOHNSON: Endothelin does mediate mesangial cell con-
traction in vitro [186], but whether it does the same in vivo is
unknown. Endothelin-1 is also upregulated in several glomeru-
lar diseases, including the Thy 1 model and the remnant kidney
model [98, 99]. In the latter model, treatment with an endothelin
receptor blocker reduced glomerulosclerosis [129]. Unfortu-
nately, it also reduced the blood pressure in these animals, so it
is unclear whether the protective effect was simply due to a
reduction in blood pressure.
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